EA201891814A1 - СПОСОБЫ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИЧ И СПИДа - Google Patents

СПОСОБЫ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИЧ И СПИДа

Info

Publication number
EA201891814A1
EA201891814A1 EA201891814A EA201891814A EA201891814A1 EA 201891814 A1 EA201891814 A1 EA 201891814A1 EA 201891814 A EA201891814 A EA 201891814A EA 201891814 A EA201891814 A EA 201891814A EA 201891814 A1 EA201891814 A1 EA 201891814A1
Authority
EA
Eurasian Patent Office
Prior art keywords
aids
hiv
prevention
treatment
methods
Prior art date
Application number
EA201891814A
Other languages
English (en)
Russian (ru)
Inventor
Дария Хазуда
Майкл Д. Меллер
Джей А. Гроблер
Дебора Энн Николл-Гриффит
Original Assignee
Мерк Шарп И Доум Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп И Доум Корп. filed Critical Мерк Шарп И Доум Корп.
Publication of EA201891814A1 publication Critical patent/EA201891814A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
EA201891814A 2016-02-12 2017-02-10 СПОСОБЫ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИЧ И СПИДа EA201891814A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US201662297657P 2016-02-19 2016-02-19
PCT/US2017/017283 WO2017139519A1 (en) 2016-02-12 2017-02-10 Methods for treatment and prophylaxis of hiv and aids

Publications (1)

Publication Number Publication Date
EA201891814A1 true EA201891814A1 (ru) 2019-01-31

Family

ID=58057333

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891814A EA201891814A1 (ru) 2016-02-12 2017-02-10 СПОСОБЫ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИЧ И СПИДа

Country Status (37)

Country Link
US (4) US10537589B2 (enExample)
EP (1) EP3413897B1 (enExample)
JP (4) JP6810972B2 (enExample)
KR (4) KR20250136420A (enExample)
CN (2) CN108697727A (enExample)
AU (3) AU2017217656B2 (enExample)
BR (1) BR112018016349A2 (enExample)
CA (1) CA3013473C (enExample)
CL (1) CL2018002150A1 (enExample)
DK (1) DK3413897T3 (enExample)
DO (1) DOP2018000183A (enExample)
EA (1) EA201891814A1 (enExample)
ES (1) ES2953535T3 (enExample)
FI (1) FI3413897T3 (enExample)
GE (1) GEP20217231B (enExample)
HR (1) HRP20230935T1 (enExample)
HU (1) HUE063532T2 (enExample)
IL (1) IL260874B2 (enExample)
JO (1) JOP20170038B1 (enExample)
LT (1) LT3413897T (enExample)
MD (1) MD3413897T2 (enExample)
MX (3) MX390604B (enExample)
MY (1) MY197090A (enExample)
NI (1) NI201800083A (enExample)
NZ (1) NZ745065A (enExample)
PH (1) PH12018501712A1 (enExample)
PL (1) PL3413897T3 (enExample)
PT (1) PT3413897T (enExample)
RS (1) RS64448B1 (enExample)
SG (1) SG11201806783WA (enExample)
SI (1) SI3413897T1 (enExample)
SV (1) SV2018005733A (enExample)
TN (1) TN2018000267A1 (enExample)
TW (2) TWI822652B (enExample)
UA (1) UA126375C2 (enExample)
WO (1) WO2017139519A1 (enExample)
ZA (1) ZA201805073B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
US12297224B2 (en) * 2018-07-02 2025-05-13 Henan Genuine Biotech Co., Ltd. Crystal form, preparation method, and application of 4'-substituted nucleoside
US12005072B2 (en) 2018-07-17 2024-06-11 Merck Sharp & Dohme Llc HIV drug combination for increasing barrier against resistance
US12227536B2 (en) * 2018-12-20 2025-02-18 Merck Sharp & Dohme Llc Crystalline forms of an NRTTI compound
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
PH12021500034A1 (en) * 2019-03-06 2022-06-06 Glaxosmithkline Ip No 2 Ltd Compounds useful in hiv therapy
JP7700096B2 (ja) 2019-07-27 2025-06-30 ブリー バイオサイエンシーズ, インコーポレイテッド アデノシン誘導体及びそれを含む薬学的組成物
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE346651T1 (de) * 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
PL219609B1 (pl) 2003-02-19 2015-06-30 Masanori Baba Analogi nukleozydów przeciwwirusowych, zawierająca je kompozycja farmaceutyczna i ich zastosowania
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
WO2009126293A2 (en) * 2008-04-11 2009-10-15 Yale University Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase
WO2012099630A1 (en) * 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2017053216A2 (en) 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP6934019B2 (ja) * 2016-05-12 2021-09-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ウイルス薬を送達するための薬物送達システム
US20190388336A1 (en) * 2016-06-20 2019-12-26 Merck Sharp & Dohme Corp. Drug Delivery System for the Delivery of Antiviral Agents
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
AU2020328518A1 (en) * 2019-08-13 2022-03-10 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents
CN115843259A (zh) * 2020-05-05 2023-03-24 默沙东有限责任公司 用于递送抗病毒剂和避孕药的药物递送系统
WO2022046578A1 (en) * 2020-08-25 2022-03-03 Merck Sharp & Dohme Corp. Injectable depot compositions for the delivery of antiviral agents

Also Published As

Publication number Publication date
HRP20230935T1 (hr) 2023-11-24
US20200101098A1 (en) 2020-04-02
JP2022062170A (ja) 2022-04-19
HUE063532T2 (hu) 2024-01-28
CN108697727A (zh) 2018-10-23
MX2018009763A (es) 2018-11-29
SV2018005733A (es) 2018-12-14
PL3413897T3 (pl) 2023-10-02
JP6810972B2 (ja) 2021-01-13
HK1257347A1 (en) 2019-10-18
JOP20170038B1 (ar) 2021-08-17
KR102317570B1 (ko) 2021-10-25
JP7021314B2 (ja) 2022-02-16
LT3413897T (lt) 2023-08-25
US10537589B2 (en) 2020-01-21
KR20250136420A (ko) 2025-09-16
AU2020202866A1 (en) 2020-05-21
AU2017217656A1 (en) 2018-08-23
ZA201805073B (en) 2019-05-29
RS64448B1 (sr) 2023-09-29
US20250073254A1 (en) 2025-03-06
PH12018501712A1 (en) 2019-05-15
PT3413897T (pt) 2023-08-28
US20220331350A1 (en) 2022-10-20
US11337991B2 (en) 2022-05-24
CA3013473C (en) 2021-10-26
AU2017217656B2 (en) 2020-01-30
NI201800083A (es) 2018-10-05
AU2020202866B2 (en) 2022-04-07
NZ784982A (en) 2025-03-28
EP3413897B1 (en) 2023-06-14
KR20220126787A (ko) 2022-09-16
JP7559175B6 (ja) 2024-10-22
FI3413897T3 (fi) 2023-08-25
DOP2018000183A (es) 2018-12-31
JP2021001189A (ja) 2021-01-07
AU2022201686B2 (en) 2024-08-08
SI3413897T1 (sl) 2023-11-30
DK3413897T3 (da) 2023-09-18
CL2018002150A1 (es) 2018-12-14
MX2022002925A (es) 2023-02-10
IL260874A (enExample) 2018-09-20
MX390604B (es) 2025-03-20
MD3413897T2 (ro) 2023-11-30
BR112018016349A2 (pt) 2018-12-26
US20180055867A1 (en) 2018-03-01
MY197090A (en) 2023-05-24
UA126375C2 (uk) 2022-09-28
US12171776B2 (en) 2024-12-24
JP2019504857A (ja) 2019-02-21
JP2024001206A (ja) 2024-01-09
CN113509480A (zh) 2021-10-19
JP7559175B2 (ja) 2024-10-01
NZ745065A (en) 2023-11-24
GEP20217231B (en) 2021-03-25
EP3413897A1 (en) 2018-12-19
TN2018000267A1 (en) 2020-01-16
AU2022201686A1 (en) 2022-03-31
ES2953535T3 (es) 2023-11-14
KR20210049201A (ko) 2021-05-04
CA3013473A1 (en) 2017-08-17
TWI822652B (zh) 2023-11-21
KR20180108815A (ko) 2018-10-04
MX2022002924A (es) 2022-12-15
TW201731514A (zh) 2017-09-16
SG11201806783WA (en) 2018-09-27
TW202417010A (zh) 2024-05-01
IL260874B2 (en) 2023-10-01
WO2017139519A1 (en) 2017-08-17
IL260874B1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
EA201891814A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИЧ И СПИДа
PH12019500335A1 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
EA202190854A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
SA521431048B1 (ar) مركبات بيروليدين
JOP20180009A1 (ar) مركبات مثبط فيروس hiv
EA201892034A1 (ru) Элиминация вируса гепатита в при помощи противовирусных агентов
EA202091113A1 (ru) Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv)
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
MX393606B (es) Inhibidores de poli-adp ribosa polimerasa (parp)
EA201991349A1 (ru) Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
EA201890200A1 (ru) Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b
PH12019500432B1 (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
EA201990833A1 (ru) Соединение пиридина
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
EA201891644A1 (ru) Антибактериальные соединения и их применение
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
EA201992354A1 (ru) Аналоги бензоазепина в качестве ингибирующих агентов для тирозинкиназы брутона
MX382760B (es) Derivados de quinoleina para usarse en el tratamiento o prevencion de una infeccion viral.
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MY207239A (en) Imidazopyridinone compound
EA202190398A1 (ru) Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4
EA202190046A1 (ru) N-замещенные производные тетрагидротиенопиридина и их применение
EA201992233A1 (ru) Соединения изоксазолкарбоксамида и их применение
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
EA201991208A1 (ru) Способы лечения множественного остеохондроматоза (мо)